Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection

Sandile Cele, Laurelle Jackson, Khadija Khan, David Khoury, Thandeka Moyo-Gwete, Houriiyah Tegally, Cathrine Scheepers, Daniel Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, James Emmanuel San, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett I. Gosnell, Salim Abdool Karim, Willem Hanekom, NGS-SA, COMMIT-KZN Team, Anne von Gottberg, Jinal Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, View ORCID ProfileMiles Davenport, View ORCID ProfileTulio de Oliveira, Penny L. Moore, View ORCID ProfileAlex Sigal
doi: https://doi.org/10.1101/2021.12.08.21267417
Sandile Cele
1Africa Health Research Institute, Durban, South Africa
2School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurelle Jackson
1Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Khadija Khan
1Africa Health Research Institute, Durban, South Africa
2School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Khoury
3Kirby Institute, University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thandeka Moyo-Gwete
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
5MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Houriiyah Tegally
6KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
7Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathrine Scheepers
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
5MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Amoako
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farina Karim
1Africa Health Research Institute, Durban, South Africa
2School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mallory Bernstein
1Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gila Lustig
8Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derseree Archary
8Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Muneerah Smith
9Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yashica Ganga
1Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zesuliwe Jule
1Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kajal Reedoy
1Africa Health Research Institute, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James Emmanuel San
6KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shi-Hsia Hwa
1Africa Health Research Institute, Durban, South Africa
10Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Giandhari
6KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan M. Blackburn
9Department of Integrative Biomedical Sciences, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa
11Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernadett I. Gosnell
12Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Salim Abdool Karim
7Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Willem Hanekom
1Africa Health Research Institute, Durban, South Africa
10Division of Infection and Immunity, University College London, London, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anne von Gottberg
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
5MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jinal Bhiman
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
5MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard J. Lessells
6KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
7Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
8Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mahomed-Yunus S. Moosa
12Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine, University of KwaZulu-Natal, Durban, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Miles Davenport
3Kirby Institute, University of New South Wales, Sydney, Australia
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Miles Davenport
Tulio de Oliveira
6KwaZulu-Natal Research Innovation and Sequencing Platform, Durban, South Africa
7Centre for Epidemic Response and Innovation, School of Data Science and Computational Thinking, Stellenbosch University, Stellenbosch, South Africa
8Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
13Department of Global Health, University of Washington, Seattle, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tulio de Oliveira
Penny L. Moore
4National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg, South Africa
5MRC Antibody Immunity Research Unit, School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
8Centre for the AIDS Programme of Research in South Africa, Durban, South Africa
11Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alex Sigal
1Africa Health Research Institute, Durban, South Africa
2School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa
14Max Planck Institute for Infection Biology, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alex Sigal
  • For correspondence: alex.sigal@ahri.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The emergence of the Omicron variant (1) of SARS-CoV-2 in November 2021 in South Africa has raised concerns that, based on the large number of mutations in the spike protein and elsewhere on the virus (https://covdb.stanford.edu/page/mutation-viewer/#sec_b-1-351), this variant will have considerable escape from vaccine elicited immunity. Furthermore, several mutations in the receptor binding domain and S2 are predicted to impact transmissibility and affinity for ACE-2.

Here we investigated whether Omicron escapes antibody neutralization elicited by the Pfizer BNT162b2 mRNA vaccine and whether the virus still requires binding to the ACE2 receptor to infect cells. We used an early passage of isolated and sequence confirmed live Omicron virus isolated in South Africa. We used a human lung cell line clone (H1299-ACE2) engineered to express the ACE2 receptor (2) to both isolate the virus and test neutralization. We also tested growth in the parental H1299 which do not overexpress ACE2 and are not appreciably infectable with SARS-CoV-2 (Fig S1). The H1299-ACE2 cells were similar to Vero-E6 in titer dependent focus formation, but were considerably more sensitive (Fig S2).

We observed that Omicron infected the ACE2-expressing cells in a concentration dependent manner but did not infect the parental H1299 cells, indicating that ACE2 is required for Omicron entry (Fig. 1A). We then tested the ability of plasma from BNT162b2 vaccinated study participants to neutralize Omicron versus ancestral D614G virus in a live virus neutralization assay. We tested 14 plasma samples from 12 participants (Table S1), with 6 having no previous record of SARS-CoV-2 infection nor detectable nucleocapsid antibodies indicative of previous infection. For two of these participants, we used samples from two timepoints. The remaining 6 participants had a record of previous infection in the first SARS-CoV-2 infection wave in South Africa where infection was with ancestral D614G virus (Table S1). Geometric mean titer (GMT) FRNT50 (inverse of the plasma dilution required for 50% reduction in infection foci number) was 1321 for D614G. These samples therefore had very strong neutralization of D614G virus, consistent with sampling soon after vaccination. GMT FRNT50 for the same samples was 32 for Omicron, a 41-fold decline (Fig 1B). However, the escape was incomplete, with 5 of the participants, all previously infected, showing relatively high neutralization titers with Omicron.

Beta variant escape from BNT162b2 in a live virus neutralization assay has been reported to be substantial (3) and our own data confirmed these results (4), with about 3-fold reduction in FRNT50. The results we present here with Omicron show much more extensive escape. However, escape was incomplete in participants with higher FRNT50 due to previous infection. Previous infection, followed by vaccination or booster is likely to increase the neutralization level and likely confer protection from severe disease in Omicron infection.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Bill and Melinda Gates award INV-018944 (AS), National Institutes of Health award R01 AI138546 (AS), and South African Medical Research Council awards (AS, TdO, PLM). PLM is also supported by the South African Research Chairs Initiative of the Department of Science and Innovation and the NRF (Grant No 9834). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Blood samples were obtained from hospitalized adults with PCR confirmed SARS-CoV-2 infection and/or vaccinated individuals who were enrolled in a prospective cohort study approved by the Biomedical Research Ethics Committee at the University of KwaZulu-Natal (reference BREC/00001275/2020). Use of residual swab sample was approved by the University of the Witwatersrand Human Research Ethics Committee (HREC) (ref. M210752).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted December 09, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Sandile Cele, Laurelle Jackson, Khadija Khan, David Khoury, Thandeka Moyo-Gwete, Houriiyah Tegally, Cathrine Scheepers, Daniel Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, James Emmanuel San, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett I. Gosnell, Salim Abdool Karim, Willem Hanekom, NGS-SA, COMMIT-KZN Team, Anne von Gottberg, Jinal Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, Miles Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal
medRxiv 2021.12.08.21267417; doi: https://doi.org/10.1101/2021.12.08.21267417
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection
Sandile Cele, Laurelle Jackson, Khadija Khan, David Khoury, Thandeka Moyo-Gwete, Houriiyah Tegally, Cathrine Scheepers, Daniel Amoako, Farina Karim, Mallory Bernstein, Gila Lustig, Derseree Archary, Muneerah Smith, Yashica Ganga, Zesuliwe Jule, Kajal Reedoy, James Emmanuel San, Shi-Hsia Hwa, Jennifer Giandhari, Jonathan M. Blackburn, Bernadett I. Gosnell, Salim Abdool Karim, Willem Hanekom, NGS-SA, COMMIT-KZN Team, Anne von Gottberg, Jinal Bhiman, Richard J. Lessells, Mahomed-Yunus S. Moosa, Miles Davenport, Tulio de Oliveira, Penny L. Moore, Alex Sigal
medRxiv 2021.12.08.21267417; doi: https://doi.org/10.1101/2021.12.08.21267417

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (215)
  • Allergy and Immunology (495)
  • Anesthesia (106)
  • Cardiovascular Medicine (1095)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (274)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (500)
  • Epidemiology (9765)
  • Forensic Medicine (5)
  • Gastroenterology (480)
  • Genetic and Genomic Medicine (2308)
  • Geriatric Medicine (222)
  • Health Economics (462)
  • Health Informatics (1557)
  • Health Policy (734)
  • Health Systems and Quality Improvement (603)
  • Hematology (236)
  • HIV/AIDS (503)
  • Infectious Diseases (except HIV/AIDS) (11638)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (237)
  • Medical Ethics (67)
  • Nephrology (257)
  • Neurology (2141)
  • Nursing (134)
  • Nutrition (336)
  • Obstetrics and Gynecology (426)
  • Occupational and Environmental Health (517)
  • Oncology (1175)
  • Ophthalmology (364)
  • Orthopedics (128)
  • Otolaryngology (220)
  • Pain Medicine (146)
  • Palliative Medicine (50)
  • Pathology (311)
  • Pediatrics (695)
  • Pharmacology and Therapeutics (300)
  • Primary Care Research (266)
  • Psychiatry and Clinical Psychology (2180)
  • Public and Global Health (4653)
  • Radiology and Imaging (776)
  • Rehabilitation Medicine and Physical Therapy (457)
  • Respiratory Medicine (623)
  • Rheumatology (274)
  • Sexual and Reproductive Health (225)
  • Sports Medicine (210)
  • Surgery (251)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)